Rafael Pharmaceuticals to Present Plan for Phase 3 Trial (AVENGER 500) of devimistat (CPI-613®) in Combination with Modified FOLFIRINOX as a First Line Treatment for Metastatic Pancreatic Cancer at 2019 Gastrointestinal Cancers Symposium
Newark, NJ, Jan. 17, 2019 (GLOBE NEWSWIRE) — Rafael Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based […]